Corcept Therapeutics (NASDAQ:CORT) Upgraded at BidaskClub
Several other research analysts have also weighed in on CORT. Zacks Investment Research lowered Corcept Therapeutics from a hold rating to a sell rating and set a $14.00 price target on the stock. in a research report on Tuesday, February 4th. ValuEngine lowered Corcept Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $16.50.
NASDAQ:CORT traded up $0.04 during trading hours on Tuesday, hitting $13.27. 11,844 shares of the company’s stock traded hands, compared to its average volume of 778,442. The firm has a market cap of $1.51 billion, a P/E ratio of 18.58 and a beta of 1.25. Corcept Therapeutics has a twelve month low of $9.55 and a twelve month high of $17.48. The stock’s fifty day moving average price is $12.75 and its two-hundred day moving average price is $13.32.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Recommended Story: Rule of 72
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.